UPDATE: Barclays Downgrades Cymer, Inc. (CYMI) to Equalweight; Valuation Call
Tweet Send to a FriendGet Alerts CYMI Hot Sheet
Price: $111.94 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 13
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 13
Trade CYMI Now!
(Updated - July 18, 2012 1:14 PM EDT)
Barclays downgraded Cymer, Inc. (NASDAQ: CYMI) from Overweight to Equalweight with a price target of $60.00.
Analyst, C.J. Muse, said, "While EUV lithography remains one of our favorite product cycles and CYMI is one of the two best ways to invest in this theme, the strong performance in shares YTD (+19% vs. SOX -4%) and valuation that is now nearing our price target of $60 (12x our CY15 EPS estimate of ~$5.00) causes us to lower our rating."
For an analyst ratings summary and ratings history on Cymer, Inc. click here. For more ratings news on Cymer, Inc. click here.
Shares of Cymer, Inc. closed at $59.25 yesterday, with a 52 week range of $34.57-$62.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays downgraded Cymer, Inc. (NASDAQ: CYMI) from Overweight to Equalweight with a price target of $60.00.
Analyst, C.J. Muse, said, "While EUV lithography remains one of our favorite product cycles and CYMI is one of the two best ways to invest in this theme, the strong performance in shares YTD (+19% vs. SOX -4%) and valuation that is now nearing our price target of $60 (12x our CY15 EPS estimate of ~$5.00) causes us to lower our rating."
For an analyst ratings summary and ratings history on Cymer, Inc. click here. For more ratings news on Cymer, Inc. click here.
Shares of Cymer, Inc. closed at $59.25 yesterday, with a 52 week range of $34.57-$62.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- MKM Partners Downgrades Alkermes (ALKS) to Sell
- Janney Montgomery Scott Downgrades Cubist Pharmaceuticals (CBST) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
